To cite this paper use one of the standards below:
Binding assays are essential in drug screening, evaluating compound interactions with molecular targets, and are widely used in drug design and neurotransmitter-receptor studies. Neurotransmitters play a fundamental role in regulating motor activity, memory, behavior and brain development, with alterations in these systems often associated with dysfunctions observed in conditions such as Autism Spectrum Disorder (ASD), such as, for example, alterations in the dopaminergic system. Dopamine, the key neurotransmitter in this system, plays a crucial role in social behaviors, cognition, and the reward mechanism. Studies indicate that individuals with ASD show reduced dopaminergic responses in some brain areas and decreased dopamine release in others. These imbalances are associated with deficits in social interaction and the development of stereotyped behaviors, common in ASD. Given the limited therapeutic options for ASD, exploring bioinspired peptides like neuroVAL is crucial. This study aimed to standardize dopamine receptor binding assays to evaluate neuroVAL’s interaction with brain tissue from valproic acid (VPA)-induced ASD mice. Synaptosomes and neural membranes were extracted from female Swiss mice, following protocols approved by the Animal Ethics Committee (CEUA) of the University of Brasília. Extraction protocols, incubation time, temperature, and buffer conditions were standardized for reproducibility. Competition, saturation, and uptake assays were performed using tritiated dopamine (³H-dopamine) and neuroVAL. Results showed a significant increase in radioactive binding to dopamine receptors with the peptide, suggesting interaction and modulation. In uptake assays, the expected decrease in ³H-dopamine uptake occurred with increasing non-radioactive dopamine. Interestingly, neuroVAL slightly increased dopamine uptake, indicating potential modulatory effects. Statistical analysis suggested further investigation. This study suggests that neuroVAL may modulate dopaminergic receptors, crucial given the dopaminergic dysfunction in ASD. Standardizing binding assays is vital to accurately quantify receptor interactions in brain tissue from VPA-induced ASD mice. Despite promising results, further protocol optimization is needed for reliability. Future studies should refine assays and validate neuroVAL’s therapeutic potential for ASD treatment.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper